Surgical Conversion of Candonilimab (AK104) Plus Paclitaxel, S-1 and Apatinib for Unresectable Advanced G/GEJ Cancer

Subjects will receive AK104 until disease progression or for up to 6 cycles.

Subjects will receive apatinib until disease progression or for up to 6 cycles.

Subjects will receive paclitaxel until disease progression or for up to 6 cycles.

Subjects will receive S-1 until disease progression or for up to 6 cycles.